Literature DB >> 22871895

Blood pressure and risk of cardiovascular diseases in type 2 diabetes: further findings from the Swedish National Diabetes Register (NDR-BP II).

Jan Cederholm1, Soffia Gudbjörnsdottir, Björn Eliasson, Björn Zethelius, Katarina Eeg-Olofsson, Peter M Nilsson.   

Abstract

OBJECTIVES: Estimate risks of coronary heart disease (CHD), stroke and cardiovascular disease (CVD) with updated mean systolic (SBP) and diastolic (DBP) blood pressure in an observational study of patients with type 2 diabetes.
METHODS: Thirty-five thousand and forty-one patients treated with antihypertensive drugs, and 18 512 untreated patients, aged 30-75 years, without previous heart failure, followed for 6 years until 2009.
RESULTS: In treated patients, nonlinear splines for 6-year risk of fatal/nonfatal CHD, stroke and CVD by BP as a continuous variable showed a progressive increase with higher SBP from 140  mmHg and higher, and with DBP from 80  mmHg, with a J-shaped risk curve at lowest SBP levels, but not obviously at lowest DBP levels. Analysing intervals of SBP with 130-134  mmHg as reference at Cox regression, adjusted hazard ratios (HR) for fatal/nonfatal CHD, stroke and CVD with at least 140  mmHg were 1.22 [95% confidence interval (CI): 1.08-1.39], 1.43 (1.18-1.72), 1.26 (1.13-1.41), all P < 0.001. HR with 115-129 and 135-139  mmHg were nonsignificant, whereas increased with 100-114  mmHg, 1.96 (P < 0.001), 1.75 (P = 0.02), 2.08 (P < 0.001), respectively. With DBP 75-79  mmHg as reference, adjusted HR for fatal/nonfatal CHD, stroke and CVD with DBP 80-84  mmHg were 1.42 (1.26-1.59), 1.46 (1.24-1.72), 1.39 (1.26-1.53), all P < 0.001. Corresponding HR with DBP at least 85  mmHg were 1.70 (1.50-1.92), 2.35 (1.99-2.77), 1.87 (1.69-2.07), all P < 0.001. Corresponding HR with DBP 60-69 and 70-74  mmHg were nonsignificant. The picture was similar in 7059 patients with previous CVD and in untreated patients.
CONCLUSION: BP around 130-135/75-79  mmHg showed lower risks of cardiovascular diseases in patients with type 2 diabetes.

Entities:  

Mesh:

Year:  2012        PMID: 22871895     DOI: 10.1097/HJH.0b013e3283577bdf

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  15 in total

Review 1.  Hypertension with diabetes mellitus: significance from an epidemiological perspective for Japanese.

Authors:  Yukako Tatsumi; Takayoshi Ohkubo
Journal:  Hypertens Res       Date:  2017-07-13       Impact factor: 3.872

Review 2.  J-shaped curve for cardiovascular mortality: systolic or diastolic blood pressure?

Authors:  Nicolás Roberto Robles; Francesco Fici; Guido Grassi
Journal:  J Nephrol       Date:  2018-09-17       Impact factor: 3.902

Review 3.  Benefit of Blood Pressure Control in Diabetic Patients.

Authors:  Ulrich Kintscher
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

4.  [J curve: when lowering blood pressure becomes a hazard?].

Authors:  J Slany
Journal:  Internist (Berl)       Date:  2013-03       Impact factor: 0.743

5.  Risk factors for atrial fibrillation in type 2 diabetes: report from the Swedish National Diabetes Register (NDR).

Authors:  Björn Zethelius; Soffia Gudbjörnsdottir; Björn Eliasson; Katarina Eeg-Olofsson; Ann-Marie Svensson; Jan Cederholm
Journal:  Diabetologia       Date:  2015-06-19       Impact factor: 10.122

6.  Blood pressure level and risk of major cardiovascular events and all-cause of mortality in patients with type 2 diabetes and renal impairment: an observational study from the Swedish National Diabetes Register.

Authors:  Hanri Afghahi; Maria K Svensson; Mirnabi Pirouzifard; Björn Eliasson; Ann-Marie Svensson
Journal:  Diabetologia       Date:  2015-03-14       Impact factor: 10.122

7.  Impact of ethnicity on progress of glycaemic control in 131,935 newly diagnosed patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register.

Authors:  Araz Rawshani; Ann-Marie Svensson; Annika Rosengren; Björn Zethelius; Björn Eliasson; Soffia Gudbjörnsdottir
Journal:  BMJ Open       Date:  2015-06-05       Impact factor: 2.692

Review 8.  Clinical implications of the 2013 ESH/ESC hypertension guidelines: targets, choice of therapy, and blood pressure monitoring.

Authors:  Sverre E Kjeldsen; Tonje A Aksnes; Luis M Ruilope
Journal:  Drugs R D       Date:  2014-06

9.  Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register.

Authors:  Nils Ekström; Jan Cederholm; Björn Zethelius; Björn Eliasson; Eva Fhärm; Olov Rolandsson; Mervete Miftaraj; Ann-Marie Svensson; Soffia Gudbjörnsdottir
Journal:  BMJ Open       Date:  2013-04-20       Impact factor: 2.692

10.  Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.

Authors:  Hans-Ulrich Häring; Ludwig Merker; Elke Seewaldt-Becker; Marc Weimer; Thomas Meinicke; Hans J Woerle; Uli C Broedl
Journal:  Diabetes Care       Date:  2013-08-20       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.